Metastasis

Metastasis describes the process by which cancer cells spread from a primary tumour site to distant organs through invasion of surrounding tissue, entry into blood or lymphatic circulation, survival during transit, extravasation into new tissue, and establishment of secondary tumours. This multistep biological phenomenon represents the primary cause of cancer-related mortality, as metastatic disease is often more resistant to therapy, more heterogeneous, and more difficult to eradicate than localised tumours.

The biopharmaceutical industry prioritises metastasis research and therapeutic development given its profound impact on patient outcomes across solid malignancies. Drug development strategies include targeting tumour cell migration and invasion pathways, inhibiting angiogenesis, modulating the tumour microenvironment to prevent colonisation, and enhancing immune-mediated elimination of disseminated tumour cells. Clinical trial endpoints increasingly incorporate metastasis-free survival and minimal residual disease detection to assess therapy impact earlier in disease course. Biomarker development supports identifying patients at high risk of metastasis through genomic signatures or circulating tumour DNA. As understanding deepens regarding metastatic niches, immune interactions, and early dissemination mechanisms, metastasis-focused interventions continue evolving as essential components of oncology drug development.